Rapt Therapeutics, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
RAPT Therapeutics reported Q3 2025 results, highlighting positive Phase 2 data for ozureprubart in CSU and a successful $234.4 million public offering to fund ongoing clinical development.
RAPT Therapeutics reported a reduced net loss in Q2 2025, driven by lower R&D expenses following the termination of its zelnecirnon program, while continuing development of RPT904 and tivumecirnon.
10-Q: RAPT Therapeutics Reports Q1 2025 Financial Results, Highlights RPT904 and Tivumecirnon Development
RAPT Therapeutics reports a net loss of $17.2 million for Q1 2025, focusing on advancing RPT904 and tivumecirnon while managing cash resources.
RAPT Therapeutics reports a net loss of $18.4 million for the third quarter of 2024, alongside strategic program adjustments and a workforce reduction.
RAPT Therapeutics' Q2 2024 results reveal a net loss of $58.2 million, alongside clinical trial holds and a significant workforce reduction.
RAPT Therapeutics reported its first quarter 2024 financial results, which included a net loss of $30.5 million, while also addressing clinical holds on key drug trials.